Hansa Biopharma (BATS-CHIXE:HNSAS) - Hisse Senedi Fiyatı, Haberler ve Analizler

HNSAS Stoklara Genel Bakış

A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. Daha fazla detay

HNSAS temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Kazançların yılda 47.33% oranında artması öngörülüyor

Risk Analizi

Negatif hissedar öz sermayesi

Hisse senetleri oldukça likit değildir

Hansa Biopharma AB (publ) Rakipler

Avacta Group

AIM:AVCT

UK£170.1m

Bioventix

AIM:BVXP

UK£195.7m

Arecor Therapeutics

AIM:AREC

UK£28.3m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Hansa Biopharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 21.04
52 Haftanın En Yüksek Seviyesi	SEK 57.55
52 Haftanın En Düşük Seviyesi	SEK 21.04
Beta	1.18
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-65.42%
33 Yıllık Değişim	-90.71%
5 Yıllık Değişim	-91.43%
Halka arzdan bu yana değişim	-86.89%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	HNSAS	GB Biotechs	GB Pazar
7D	0%	-5.2%	0.8%
1Y	-65.4%	-20.1%	6.6%

Getiri vs. Endüstri: HNSAS geçen yıl % -20.1 oranında getiri sağlayan UK Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: HNSAS geçen yıl % 6.6 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is HNSAS's price volatile compared to industry and market?
HNSAS volatility
HNSAS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: HNSAS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: HNSAS 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2007	168	Søren Tulstrup	www.hansabiopharma.com

Hansa Biopharma AB (publ) Temel Bilgiler Özeti

Hansa Biopharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HNSAS temel i̇stati̇sti̇kler
Piyasa değeri	SEK 1.72b
Kazançlar(TTM)	-SEK 855.93m
Gelir(TTM)	SEK 114.45m

15.0x

P/S Oranı

-2.0x

F/K Oranı

HNSAS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HNSAS gelir tablosu (TTM)
Gelir	SEK 114.45m
Gelir Maliyeti	SEK 49.55m
Brüt Kâr	SEK 64.90m
Diğer Giderler	SEK 920.83m
Kazançlar	-SEK 855.93m

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

Feb 02, 2024

Hisse başına kazanç (EPS)	-16.32
Brüt Marj	56.70%
Net Kâr Marjı	-747.87%
Borç/Özkaynak Oranı	-1,457.5%

HNSAS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

HNSAS Stoklara Genel Bakış

Ödüller

Risk Analizi

Hansa Biopharma AB (publ) Rakipler

AIM:AVCT

UK£170.1m

AIM:BVXP

UK£195.7m

AIM:AREC

UK£28.3m

AIM:TRX

UK£40.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Recent updates

Hansa Biopharma AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

Hansa Biopharma's Hnsa-5487 Achieves Rapid and Highly Robust Igg Reduction by More Than 95% and Clear Redosing Potential in First-In-Human Trial

Hansa Biopharma AB (publ) to Report Nine Months, 2025 Results on Oct 23, 2025

Matthew Shaulis, Chief Commercial Officer and US President Decides to Leave Hansa Biopharma AB in Late September

Hansa Biopharma AB (publ) to Report Q1, 2025 Results on Apr 17, 2025

Hansa Biopharma AB (publ) Announces Board Appointments

Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 372.1536 million.

Hansa Biopharma AB (Publ) Announces CFO Changes

Hansa Biopharma AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Hansa Biopharma AB (publ), Annual General Meeting, Jun 27, 2024

Hansa Biopharma AB (Publ) Provides Earnings Guidance for the Fourth Quarter and Full Year 2023

Hansa Biopharma Announces Full Results from 16-HMedIdeS-12 Phase 2 Trial in Patients with Antibody Mediated Rejection Episodes Following Kidney Transplantation

Hansa Biopharma Nomination Committee Formed

Hansa Biopharma Announces Positive High-Level Data from the 15-HMedIdeS-09 Phase 2 Trial

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hahansa Biopharma AB (Publ) Announces Resignation of Donato Spota as Chief Financial Officer, Effective 28 February 2024

Hansa Biopharma Provides Update on ConfIdeS Phase 3 Trial of Imlifidase in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma Announces Encouraging High-Level Results for First-In-Human Trial of HNSA-5487

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma, Effective 1 December 2023

Hitto Kaufmann Appointed Chief Scientific Officer of Hansa Biopharma

Hansa Biopharma AB (publ) to Report Q1, 2024 Results on Apr 17, 2024

Hansa Biopharma Announces First Patient Treated with Imlifidase in an Investigator-Initiated Phase 2 Study in Anca-Associated Vasculitis

Hansa Biopharma Receives Provisionally Approval in Australia as Desensitization Treatment in Highly Sensitized Patients Prior to Kidney Transplantation

Hansa Biopharma Announces First Patient Dosed with Imlifidase in a Global Pivotal Phase 3 Trial in Anti-Inaugular Basement Membrane (anti-GBM) Disease

First quarter 2023 earnings released

Hansa Biopharma Announces Planned Departure of Chief Scientific Officer Christian Kjellman

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma Announces Positive Reimbursement Decision for Idefirix[®] (Imlifidase) in the Czech Republic

Hansa Biopharma AB (publ) Announces Formation of Nomination Committee

Hansa Biopharma AB (publ) has completed a Follow-on Equity Offering.

Hansa Biopharma AB (Publ) Announces Positive Reimbursement Decision in Italy for Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Patients in Kidney Transplantation

Hansa Biopharma AB Announces Positive Topline Data from the Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Hansa Biopharma AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

The Scottish Medicines Consortium Recommends Use of Hansa Biopharma's Idefirix[®] (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix in Highly Sensitized Kidney Transplant Patients

Second quarter 2022 earnings released: kr3.82 loss per share (vs kr2.98 loss in 2Q 2021)

Hansa Biopharma AB (publ) announced that it has received $70 million in funding from NovaQuest Capital Management, L.L.C.

Hansa Biopharma Announces First Patient Treated in the Post-Authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Appoints Peter Nicklin as A New Member of the Board of Director

NICE Recommends Use of Hansa Biopharma's Idefirix (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients

Hansa Biopharma AB (publ) Announces Ulf Wiinberg Not to Stand for Re-Election as Director

Hansa Biopharma Completes Enrollment in Imlifidase Phase 2 Study in Antibody Mediated Rejection (AMR) Episodes Post Kidney Transplantation

Hansa Biopharma Announces Temporary Marketing Authorization in Switzerland for Idefirix (Imlifidase) in Kidney Transplantation

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Hansa Biopharma AB (publ) Temel Bilgiler Özeti

15.0x

-2.0x

Kazanç ve Gelir